Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date
This article was originally published in The Pink Sheet Daily
Executive SummaryIn addition to upfront and milestone payments, deal also includes effective royalties above 30 percent of annual net sales.
You may also be interested in...
The obesity pill will be priced at a slight premium to Vivus’ rival drug Qsymia, but Arena CEO says the amount patients will actually pay will vary based on coupon and rebate programs.